Semaglutide was chosen for this study as it is a glucagon-like peptide 1 (GLP-1) analogue that is currently approved for blood glucose management in type 2 diabetes [3] and chronic weight management for overweight and obesity [30]. Here, GCG is linked to obesity disorder.